

Pr **DOJOLVI**[®]

Triheptanoin Oral Liquid

QUEBEC

Ultragenyx Canada would like to announce that PrDOJOLVI[®] (triheptanoin) is covered by RAMQ* for eligible patients with LC-FAOD based on the reimbursement criteria detailed below through Quebec's Institut national d'excellence en santé et en services sociaux (INESSS).

What Is DOJOLVI[®] and How Does It Work?

DOJOLVI[®] (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Please consult the Product Monograph at https://dojolvihcp.ca/wp-content/uploads/pdfs/Dojolvi_Final_PM.pdf for important information on contraindications, warnings and precautions, the conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling us at 1-833-388-5872.

The DOJOLVI[®] Reimbursement Criteria for the [Quebec INESSS](#) Are as Follows:

Conditions for Reimbursement

For the treatment of long-chain fatty acid oxidation disorders. At treatment initiation, the patient must:

- have a confirmed diagnosis of LC-FAOD and
- follow a diet that is low in long-chain fatty acids and high in carbohydrates and
- present with:
 - › severe symptoms, such as rhabdomyolysis, cardiomyopathy, hepatic impairment, episodes of hypoglycemia or significant exercise intolerance that limits function, despite treatment with medium-chain triglyceride (MCT) oil supplementation or
 - › severe acute decompensation that is life-threatening, in the neonatal or infant form of the disease

The initial request is authorized for a maximum period of 6 months.

When requesting continuation of treatment, the physician must provide data demonstrating the treatment's beneficial effects (e.g., reduced hospitalizations, reduced creatine kinase levels, or improved left ventricular ejection fraction compared to baseline values).

Subsequent requests are authorized for a maximum period of 12 months.

The daily dose of triheptanoin must not exceed 35% of the patient's total prescribed daily caloric intake (DCI).

Note that triheptanoin is not to be used in combination with an MCT oil.

For more information on applying for DOJOLVI® coverage, we can arrange an appointment at your convenience, or you can visit the [UltraCare website](#). You can also find the [UltraCare Enrolment Form](#) on the UltraCare website.

* Official Mark of the Régie de l'assurance maladie du Québec.